Ammoren E Dohm1, Ryan Hughes2, William Wheless2, Michael Lecompte2, Claire Lanier2, Jimmy Ruiz3, Kounosuke Watabe4, Fei Xing4, Jing Su5, Christina Cramer2, Adrian Laxton6, Stephen Tatter6, Michael D Chan2. 1. Department of Radiation Oncology, Wake Forest School of Medicine, 1 Medical Center Boulevard, Winston-Salem, NC, 27157, USA. adohm@wakehealth.edu. 2. Department of Radiation Oncology, Wake Forest School of Medicine, 1 Medical Center Boulevard, Winston-Salem, NC, 27157, USA. 3. Department of Medicine (Hematology & Oncology), Wake Forest School of Medicine, Winston-Salem, NC, USA. 4. Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC, USA. 5. Division of Public Health Sciences, Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA. 6. Department of Neurosurgery, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Abstract
PURPOSE: The purpose of this study was to retrospectively evaluate the new treatment paradigm of staged stereotactic radiosurgery (SRS) for the treatment of large brain metastases (BM) compared to the standard of surgical resection followed by SRS. METHODS: We evaluated 78 patients with large BM treated 2012-2017 with surgical resection and postoperative SRS (surgery + SRS) or staged SRS separated by 1 month. Overall survival (OS) was estimated using the Kaplan Meier method and compared across groups using the log-rank test. Cumulative incidence of neurologic death and local and distant brain failure (LF, DBF) were estimated using competing risk methodology. RESULTS: Forty patients were treated with surgery + SRS and 38 patients were treated with staged SRS. Median follow-up was 23.2 months (95% CI 20.5-39.3). Median OS was 13.2 months for staged SRS compared to surgery + SRS 9.7 months (p = 0.53). Cumulative incidence of neurologic death at 1 year was 23% after surgery + SRS, 27% after staged SRS (p = 0.69); cumulative incidence of LF at 1 year was 6% and 8% (p = 0.65) and 1-year DBF was 59% and 21% (p ≤ 0.01). Overall rates of leptomeningeal failure and radiation necrosis were similar between the groups (p = 0.63 and p = 1.0). CONCLUSIONS: Though surgery and postoperative SRS is the standard, staged SRS represents an attractive treatment paradigm for treating large BM without sacrificing LC or survival, and potentially decreases DBF. Prospective studies are needed to validate these findings.
PURPOSE: The purpose of this study was to retrospectively evaluate the new treatment paradigm of staged stereotactic radiosurgery (SRS) for the treatment of large brain metastases (BM) compared to the standard of surgical resection followed by SRS. METHODS: We evaluated 78 patients with large BM treated 2012-2017 with surgical resection and postoperative SRS (surgery + SRS) or staged SRS separated by 1 month. Overall survival (OS) was estimated using the Kaplan Meier method and compared across groups using the log-rank test. Cumulative incidence of neurologic death and local and distant brain failure (LF, DBF) were estimated using competing risk methodology. RESULTS: Forty patients were treated with surgery + SRS and 38 patients were treated with staged SRS. Median follow-up was 23.2 months (95% CI 20.5-39.3). Median OS was 13.2 months for staged SRS compared to surgery + SRS 9.7 months (p = 0.53). Cumulative incidence of neurologic death at 1 year was 23% after surgery + SRS, 27% after staged SRS (p = 0.69); cumulative incidence of LF at 1 year was 6% and 8% (p = 0.65) and 1-year DBF was 59% and 21% (p ≤ 0.01). Overall rates of leptomeningeal failure and radiation necrosis were similar between the groups (p = 0.63 and p = 1.0). CONCLUSIONS: Though surgery and postoperative SRS is the standard, staged SRS represents an attractive treatment paradigm for treating large BM without sacrificing LC or survival, and potentially decreases DBF. Prospective studies are needed to validate these findings.
Entities:
Keywords:
Distant brain failure; Large brain metastases; Leptomeningeal failure; Local control; Overall survival; Stereotactic radiosurgery; Surgery and postoperative resection
Authors: Eric Ojerholm; John Y K Lee; Jayesh P Thawani; Denise Miller; Donald M O'Rourke; Jay F Dorsey; Geoffrey A Geiger; Suneel Nagda; James D Kolker; Robert A Lustig; Michelle Alonso-Basanta Journal: J Neurosurg Date: 2014-12 Impact factor: 5.115
Authors: Matthew D Johnson; Vladimir Avkshtol; Andrew M Baschnagel; Kurt Meyer; Hong Ye; Inga S Grills; Peter Y Chen; Ann Maitz; Rick E Olson; Daniel R Pieper; Daniel J Krauss Journal: Int J Radiat Oncol Biol Phys Date: 2015-11-19 Impact factor: 7.038
Authors: Lilyana Angelov; Alireza M Mohammadi; Elizabeth E Bennett; Mahmoud Abbassy; Paul Elson; Samuel T Chao; Joshua S Montgomery; Ghaith Habboub; Michael A Vogelbaum; John H Suh; Erin S Murphy; Manmeet S Ahluwalia; Sean J Nagel; Gene H Barnett Journal: J Neurosurg Date: 2017-09-22 Impact factor: 5.115
Authors: Natalie A Lockney; Diana G Wang; Philip H Gutin; Cameron Brennan; Viviane Tabar; Ase Ballangrud; Xin Pei; Timothy A Chan; Yoshiya Yamada; T Jonathan Yang; Kathryn Beal Journal: Radiother Oncol Date: 2017-04-05 Impact factor: 6.280
Authors: Emory R McTyre; Adam G Johnson; Jimmy Ruiz; Scott Isom; John T Lucas; William H Hinson; Kounosuke Watabe; Adrian W Laxton; Stephen B Tatter; Michael D Chan Journal: Neuro Oncol Date: 2017-04-01 Impact factor: 12.300
Authors: Colette J Shen; Megan N Kummerlowe; Kristin J Redmond; Daniele Rigamonti; Michael K Lim; Lawrence R Kleinberg Journal: Int J Radiat Oncol Biol Phys Date: 2016-02-09 Impact factor: 7.038
Authors: Andrew J Huang; Karen E Huang; Brandi R Page; Diandra N Ayala-Peacock; John T Lucas; Glenn J Lesser; Adrian W Laxton; Stephen B Tatter; Michael D Chan Journal: J Neurooncol Date: 2014-07-22 Impact factor: 4.130
Authors: Taoran Cui; Joseph Weiner; Shabbar Danish; Anupama Chundury; Nisha Ohri; Ning Yue; Xiao Wang; Ke Nie Journal: Front Oncol Date: 2022-06-30 Impact factor: 5.738
Authors: Claire M Lanier; Michael Lecompte; Chase Glenn; Ryan T Hughes; Scott Isom; Wendy Jenkins; Christina K Cramer; Michael Chan; Stephen B Tatter; Adrian W Laxton Journal: Cureus Date: 2021-11-28
Authors: Michael C LeCompte; Ryan T Hughes; Michael Farris; Adrianna Masters; Michael H Soike; Claire Lanier; Chase Glenn; Christina K Cramer; Kounosuke Watabe; Jing Su; Jimmy Ruiz; Christopher T Whitlow; Ge Wang; Adrian W Laxton; Stephen B Tatter; Michael D Chan Journal: J Neurooncol Date: 2020-01-01 Impact factor: 4.130
Authors: Johannes Kerschbaumer; Aleksandrs Krigers; Matthias Demetz; Daniel Pinggera; Julia Klingenschmid; Nadine Pichler; Claudius Thomé; Christian F Freyschlag Journal: J Neurooncol Date: 2022-04-13 Impact factor: 4.506
Authors: Eduardo E Lovo; Leonel B Torres; Fidel J Campos; Victor E Caceros; Kaory E Barahona; Mario H Minervini; William A Reyes Journal: Cureus Date: 2019-08-24
Authors: David T Krist; Anant Naik; Charee M Thompson; Susanna S Kwok; Mika Janbahan; William C Olivero; Wael Hassaneen Journal: Neurooncol Adv Date: 2022-03-09